S&P 500   4,351.73 (+0.50%)
DOW   34,126.78 (+0.17%)
QQQ   359.50 (+0.46%)
AAPL   174.88 (+0.55%)
MSFT   319.04 (-0.15%)
META   302.41 (+2.26%)
GOOGL   131.24 (+0.61%)
AMZN   130.43 (+0.85%)
TSLA   254.13 (-0.61%)
NVDA   414.24 (+0.99%)
NIO   8.61 (+1.89%)
BABA   88.67 (+5.42%)
AMD   97.19 (+1.12%)
T   15.15 (-1.05%)
F   12.60 (+3.28%)
MU   68.81 (+1.34%)
CGC   0.80 (+4.91%)
GE   112.97 (-0.02%)
DIS   82.41 (-0.39%)
AMC   7.72 (+0.26%)
PFE   32.56 (-0.88%)
PYPL   58.56 (-0.10%)
NFLX   382.91 (-0.32%)
S&P 500   4,351.73 (+0.50%)
DOW   34,126.78 (+0.17%)
QQQ   359.50 (+0.46%)
AAPL   174.88 (+0.55%)
MSFT   319.04 (-0.15%)
META   302.41 (+2.26%)
GOOGL   131.24 (+0.61%)
AMZN   130.43 (+0.85%)
TSLA   254.13 (-0.61%)
NVDA   414.24 (+0.99%)
NIO   8.61 (+1.89%)
BABA   88.67 (+5.42%)
AMD   97.19 (+1.12%)
T   15.15 (-1.05%)
F   12.60 (+3.28%)
MU   68.81 (+1.34%)
CGC   0.80 (+4.91%)
GE   112.97 (-0.02%)
DIS   82.41 (-0.39%)
AMC   7.72 (+0.26%)
PFE   32.56 (-0.88%)
PYPL   58.56 (-0.10%)
NFLX   382.91 (-0.32%)
S&P 500   4,351.73 (+0.50%)
DOW   34,126.78 (+0.17%)
QQQ   359.50 (+0.46%)
AAPL   174.88 (+0.55%)
MSFT   319.04 (-0.15%)
META   302.41 (+2.26%)
GOOGL   131.24 (+0.61%)
AMZN   130.43 (+0.85%)
TSLA   254.13 (-0.61%)
NVDA   414.24 (+0.99%)
NIO   8.61 (+1.89%)
BABA   88.67 (+5.42%)
AMD   97.19 (+1.12%)
T   15.15 (-1.05%)
F   12.60 (+3.28%)
MU   68.81 (+1.34%)
CGC   0.80 (+4.91%)
GE   112.97 (-0.02%)
DIS   82.41 (-0.39%)
AMC   7.72 (+0.26%)
PFE   32.56 (-0.88%)
PYPL   58.56 (-0.10%)
NFLX   382.91 (-0.32%)
S&P 500   4,351.73 (+0.50%)
DOW   34,126.78 (+0.17%)
QQQ   359.50 (+0.46%)
AAPL   174.88 (+0.55%)
MSFT   319.04 (-0.15%)
META   302.41 (+2.26%)
GOOGL   131.24 (+0.61%)
AMZN   130.43 (+0.85%)
TSLA   254.13 (-0.61%)
NVDA   414.24 (+0.99%)
NIO   8.61 (+1.89%)
BABA   88.67 (+5.42%)
AMD   97.19 (+1.12%)
T   15.15 (-1.05%)
F   12.60 (+3.28%)
MU   68.81 (+1.34%)
CGC   0.80 (+4.91%)
GE   112.97 (-0.02%)
DIS   82.41 (-0.39%)
AMC   7.72 (+0.26%)
PFE   32.56 (-0.88%)
PYPL   58.56 (-0.10%)
NFLX   382.91 (-0.32%)
NASDAQ:BJDX

Bluejay Diagnostics (BJDX) Stock Forecast, Price & News

$4.29
-0.43 (-9.11%)
(As of 10:21 AM ET)
Compare
Today's Range
$4.20
$4.88
50-Day Range
$3.06
$8.82
52-Week Range
$2.90
$18.91
Volume
74,130 shs
Average Volume
435,396 shs
Market Capitalization
$4.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Bluejay Diagnostics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
9.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Bluejay Diagnostics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.89) to ($2.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars


BJDX stock logo

About Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

BJDX Price History

BJDX Stock News Headlines

Bluejay Diagnostics (NASDAQ:BJDX) Trading Down 0.6%
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
BJDX: FDA Meeting Confirms Pathway
Reverse ‘money machines’ popping up across America
If you’ve been to a concert venue, stadium, or airport, you’ve almost certainly walked by one without knowing. The experts are calling it a 'Reverse ATM' Why are these machines suddenly appearing out of nowhere? And what does it mean for your money?
Bluejay Diagnostics Announces Reverse Stock Split
Why Is Bluejay Diagnostics (BJDX) Stock Up 17% Today?
BJDX: Orchestrating a New Testing Standard
8-K: Bluejay Diagnostics, Inc.
Bluejay Diagnostics GAAP EPS of -$0.12
Up In the Blue Seats Podcast
See More Headlines
Receive BJDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

BJDX Company Calendar

Last Earnings
8/14/2023
Today
9/22/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BJDX
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
$-9,300,000.00
Pretax Margin
-3,945.38%

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$11.45 per share

Miscellaneous

Free Float
542,000
Market Cap
$4.81 million
Optionable
Not Optionable
Beta
1.10
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Indranil Dey (Age 59)
    Pres, CEO & Director
    Comp: $413.16k
  • Mr. Kenneth R. Fisher CPA (Age 44)
    Chief Financial Officer
    Comp: $366.18k
  • Dr. Jason Cook (Age 40)
    Chief Technology Officer
    Comp: $278.42k
  • Mr. Les DeLuca
    VP of Operations
  • Eryn Graham
    Marketing Mang.
  • Mr. Kevin Vance (Age 66)
    Chief Commercial Officer
  • Mark W. Feinberg
    Chief Medical Advisor
  • Dr. Mark W. Feinberg M.D.
    Chief Medical Advisor
  • Ryan McSeveney
    Corp. Controller













BJDX Stock - Frequently Asked Questions

Should I buy or sell Bluejay Diagnostics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bluejay Diagnostics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BJDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BJDX, but not buy additional shares or sell existing shares.
View BJDX analyst ratings
or view top-rated stocks.

How have BJDX shares performed in 2023?

Bluejay Diagnostics' stock was trading at $7.5980 at the beginning of the year. Since then, BJDX stock has decreased by 37.9% and is now trading at $4.72.
View the best growth stocks for 2023 here
.

When is Bluejay Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our BJDX earnings forecast
.

How were Bluejay Diagnostics' earnings last quarter?

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) released its earnings results on Monday, August, 14th. The company reported ($2.75) earnings per share for the quarter, missing the consensus estimate of ($1.50) by $1.25.

When did Bluejay Diagnostics' stock split?

Bluejay Diagnostics's stock reverse split on Monday, July 24th 2023. The 1-20 reverse split was announced on Monday, July 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Bluejay Diagnostics IPO?

(BJDX) raised $22 million in an initial public offering (IPO) on Wednesday, November 10th 2021. The company issued 2,160,000 shares at $10.00 per share.

What is Bluejay Diagnostics' stock symbol?

Bluejay Diagnostics trades on the NASDAQ under the ticker symbol "BJDX."

How do I buy shares of Bluejay Diagnostics?

Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bluejay Diagnostics' stock price today?

One share of BJDX stock can currently be purchased for approximately $4.72.

How much money does Bluejay Diagnostics make?

Bluejay Diagnostics (NASDAQ:BJDX) has a market capitalization of $4.81 million and generates $250,000.00 in revenue each year. The company earns $-9,300,000.00 in net income (profit) each year or ($10.55) on an earnings per share basis.

How can I contact Bluejay Diagnostics?

The official website for the company is www.bluejaydx.com. The company can be reached via phone at 844-327-7078 or via email at ir@bluejaydx.com.

This page (NASDAQ:BJDX) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -